139 related articles for article (PubMed ID: 38377859)
1. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
2. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
3. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C; Wang J; Pan J; Liang C; Zhou C; Wu J; Song S; Cui L; Zhang L; Liu Y; Dai B
BMC Nephrol; 2023 Sep; 24(1):280. PubMed ID: 37740193
[TBL] [Abstract][Full Text] [Related]
5. Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.
Zhu F; Chu X; Guo Y; Li Y; Cao C; Wu J; Xu H; Deng X; Li J; Liu X; Yao Y; Zeng R
Am J Transl Res; 2021; 13(7):7622-7631. PubMed ID: 34377239
[TBL] [Abstract][Full Text] [Related]
6. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy.
Xing HL; Ma DH; Li J; Xu QY; Ji LK; Zhu QJ; Luo YQ; Guo MH
Front Pharmacol; 2024; 15():1286422. PubMed ID: 38420195
[No Abstract] [Full Text] [Related]
8. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience.
Wang YW; Wang XH; Wang HX; Yu RH
World J Clin Cases; 2023 Jan; 11(3):566-575. PubMed ID: 36793628
[TBL] [Abstract][Full Text] [Related]
9. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
10. Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.
Bagchi S; Subbiah AK; Bhowmik D; Mahajan S; Yadav RK; Kalaivani M; Singh G; Dinda A; Kumar Agarwal S
Clin Kidney J; 2018 Jun; 11(3):337-341. PubMed ID: 29942496
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
12. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
13. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study.
Liu Y; Zhang S; Hu R; Li C; Chen G; Shi X; Liu Y; Zheng K; Li H; Wen Y; Li X; Li X; Xia P; Qin Y
Int J Gen Med; 2023; 16():1983-1993. PubMed ID: 37251282
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
17. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
[TBL] [Abstract][Full Text] [Related]
19. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
20. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]